These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21388580)

  • 1. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
    Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
    Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.
    Ray Chaudhuri K; Martinez-Martin P; Antonini A; Brown RG; Friedman JH; Onofrj M; Surmann E; Ghys L; Trenkwalder C
    Parkinsonism Relat Disord; 2013 Jul; 19(7):660-5. PubMed ID: 23557594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rotigotine on Parkinson's disease-related sleep disturbances.
    Antonini A; Calandrella D; Merello M; Koutsikos K; Pilleri M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2571-80. PubMed ID: 24138154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
    Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
    Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
    Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
    J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 19. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
    Wang Y; Yang YC; Lan DM; Wu H-; Zhao ZX
    Sleep Breath; 2017 May; 21(2):319-325. PubMed ID: 27726069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.